Official Title
To Demonstrate That Lactobacillus Reuteri ATCC PTA 4659 Survives Passage Through the Gastrointestinal Tract of Humans
Phase
N/ALead Sponsor
Good Food Practice ABStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Recovery of Lactobacillus Reuteri ATCC PTA 4659 The Safety of Lactobacillus Reuteri ATCC PTA 4659Intervention/Treatment
Probiotic strain ATCC PTA 4659Study Participants
30The purpose of this study is to determine the effects of a sachet containing Lactobacillus Reuteri ATCC PTA 4659 on the recovery of live Lactobacillus reuteri in fecal samples after 7, 14 and 28 days supplementation as well as 14 days wash out compared to the same sachet without the probiotic bacteria as placebo control.
This study is the first to investigate the relative colonisation of the human GI tract by L Reuteri ATCC PTA 4659. Simple demonstration that they survive passage is the first step in development of potential new probiotics, which is necessary before these strains can be considered for continued testing in probiotic food matrices. The aim of this study will evaluate the safety and tolerability of Lactobacillus Reuteri in healthy adult subjects.
Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
Placebo control without probiotics ATCC PTA 4659
Inclusion Criteria: Males and females Age 18-65 years BMI 19-33 Hb 120 g/women 130 g/l for men Healthy assessed by screening tests and physical examination Signed informed consent and bio bank consent Exclusion Criteria: Participation in a clinical study within 90 days prior screening use of antibiotics 2 weeks before baseline Pregnant or lactating